Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2039

Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.

Patents
1,782

Quick answer

1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10208046

    Nitrogen-containing heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10208016

    1-sulfonyl piperidine derivatives as modulators of prokineticin receptors

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10206921

    Methods and compositions for treating a subject for central nervous system (CNS) injury

    The Regents of the University of California · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10206986

    Annexin II variant compositions and methods

    Regents of the University of Minnesota · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10208012

    Compounds for treating inflammatory and hyperproliferative diseases

    The Board of Regents of the University of Texas System · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10208074

    Pyrazole compounds and method for making and using the compounds

    Rigel Pharmaceuticals, Inc. · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10206886

    Lipid nanoparticles for wound healing

    PRAXIS BIOPHARMA RESEARCH INSTITUTE · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10207013

    Gadolinium-based contrast agents for sensitive detection of Zn2+ with MRI

    The Board of Regents of the University of Texas System · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10208103

    Use of HDL-related molecules to treat and prevent proinflammatory conditions

    The Regents of the University of California · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10209255

    Method for identifying a bacterial infection

    University College Cardiff Consultants Limited · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10208100

    Angiopoietin-2 specific TIE2 receptor

    United Kingdom Research and Innovation · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10206995

    Live attenuated virus vaccines for la crosse virus and other bunyaviridae

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10208307

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10207000

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10211414

    Phosphorescent tetradentate metal complexes having modified emission spectra

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10206877

    Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

    Vertex Pharmaceuticals Incorporated · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10206953

    Ameliorating nervous systems disorders

    The Regents of the University of California · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10208040

    Fused imidazo-piperidine JAK inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10206957

    Use of gram negative species to treat atopic dermatitis

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10208075

    Pyrazole compounds and method for making and using the compounds

    Rigel Pharmaceuticals, Inc. · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10206932

    Natural combination hormone replacement formulations and therapies

    Compass Therapeutics LLC · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10206379

    Non-human animals having a humanized signal-regulatory protein gene

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10206875

    Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

    Northwestern University · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10206913

    4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

    Theravance Biopharma R&D IP, LLC · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10208081

    Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10208111

    Alpha-synuclein antibodies and uses thereof

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10207993

    Compounds as anti-tubercular agents

    DRUG DISCOVERY RESEARCH CENTRE · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10208059

    Heterocyclic modulators of HIF activity for treatment of disease

    The Board of Regents of the University of Texas System · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10206924

    Small molecule inhibitors of EGFR and PI3K

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10207003

    Liquid pentablock co-polymer formulations for sustained delivery of therapeutics

    inovion, Inc. · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10206897

    Creatine ester anti-inflammatory compounds and formulations

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10206933

    Non-hormonal steroid modulators of NF-kB for treatment of disease

    ReveraGen BioPharma, Inc. · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10208089

    Modulation of complement activity

    RA PHARMACEUTICALS, INC. · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. EP 3442949

    KONTRASTMITTEL

    BRACCO IMAGING SPA [IT] · Granted Wed Feb 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Feb 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 2019055264

    Macrocyclic MCL-1 inhibitors and methods of use

    ABBVIE INC [US] · Granted Thu Feb 21 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10213380

    Method of treating ear pain

    Try This First, Inc. · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10213400

    Method of administration of gamma hydroxybutyrate with monocarboxylate transporters

    Jazz Pharmaceuticals Ireland Limited · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10212923

    Humanized dipeptidyl-peptidase IV (DPP4) animals

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10213388

    Abuse resistant oral dosage forms

    Elite Laboratories, Inc. · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10214566

    Mutant adeno-associated virus virions and methods of use thereof

    The Regents of the University of California · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10213478

    Compositions and methods for the treatment of fungal infections

    Arizona Board of Regents on Behalf of Northern Arizona University · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10214726

    Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10213414

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10214522

    Anti-alphavbeta1 integrin inhibitors and methods of use

    The Regents of the University of California · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10213381

    Solid solution compositions and use in chronic inflammation

    Infirst Healthcare Limited · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10214721

    Method for making culture medium

    HON HAI PRECISION INDUSTRY CO., LTD. · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10214487

    Indole derivatives and methods of using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10213389

    Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride

    RECRO GAINESVILLE LLC · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2039?

1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.